The effect of bradykinin on the permeability and vasomotor response of pial vessels has been studied to enhance our understanding of the pathophysiological role of the kallikrein-kinin system in cerebral tissue. In travital fluorescence microscopy of the pia arachnoidea was conducted using Na + -fluorescein, FlTC-dextran, and FlTC-albumin as low and high molecular weight blood-brain barrier indicators. Massive arterial dilatation evolved immediately upon administration of bradykinin by superfusion of the exposed cerebral surface. An in crease of the arterial diameter by 40% was the maximal response found at bradykinin concentrations of 4 x 10-5 M. Arterial dilatation became attenuated with continuous superfusion of the preparation with bradykinin. In pial veins, a moderate reduction of the vessel diameter was observed, however, only after prolonged superfusion of the preparation. Bradykinin led to selective opening of the blood-brain barrier for Na + -fluorescein at super fusate concentrations of �4 x 10-7 M, but not for FlTC dextran or FlTC-albumin. Topical administration of I-iso proterenol (10-4 M) was found to prevent extravasation
Bradykinin is the active peptide of the kallikrein kinin system. It is considered an important me diator of local inflammation. Many findings on the peptide concerning peripheral circulation and per meability have been reported (Erdos, 1979; Regoli and Barabe, 1980; Grega et al. , 1981; Gawlowski et al. , 1982) . Evidence has been provided that bradykinin has a function as mediator in secondary brain damage following a primary insult, such as, e. g. , severe head injury or cerebral ischemia (Baethmann et al. , 1980 (Baethmann et al. , , 1981 Unterberg et al. , 1982; Maier Hauff et al. , 1984; of Na + -fluorescein in the presence of bradykinin concen trations of 4 x 10-6 M. Protection of the blood-brain barrier by isoproterenol was not observed when higher concentrations of bradykinin were employed. Intraca rotid infusion of bradykinin led also to a selective opening of the blood-brain barrier for Na + -fluorescein, but not for FITC-dextran or FITC-albumin. In contrast to super fusion, this route of administration did not induce changes of the vasomotor behavior of the arteries or veins. Additional experiments with B,-agonists and -an tagonists suggest that bradykinin causes the opening of the blood-brain barrier through an interaction with Bo receptors on endothelial cells, and arterial dilatation via interaction with Bo-receptors on vascular smooth muscle cells. Our findings support the concept that the release of kinins in the brain during an acute cerebral lesion me diates secondary damaging processes by the enhance ment of blood-brain barrier dysfunction. Key Words:
Blood-brain barrier-Intravital fluorescence micros copy -I soproterenol-Kallikrein-kinin system. 1984). It has recently been demonstrated that the components of the plasma kallikrein-kinin system enter the cerebral tissue in vasogenic brain edema secondary to cold injury, together with formation of kinins in areas of the focal lesion and in perifocal edematous brain (Baethmann et al. , 1981; Maier Hauff et al. , 1984) . Release of kinins was markedly enhanced by the additional cerebral ischemia evolving under these circumstances from high in tracranial pressure. Since it has been shown that direct exposure of the brain to bradykinin by ven triculocisternal perfusion induces brain edema (Un terberg et al. , 1982; Unterberg and Baethmann, 1984) , we suggest that the formation of kinins in injured brain markedly supports processes associ ated with secondary brain damage, such as, e. g. , brain edema.
The current study was performed to shed light on the specific pathophysiological mechanisms elicited by kinins in brain tissue. For that purpose, the func tion of the blood-brain barrier was studied in vivo by fluorescence microscopy together with pertinent measures of the cerebral microcirculation (Wahl et aI., 1984) . In addition, dose-effect relationships were analyzed with regard to concentrations of kinins occurring in the brain in vivo under patho logical conditions.
METHODS
The experiments were performed in 21 cats of both A detailed account of the method of intravital fluores cence microscopy of the brain as employed for the present investigations to study blood-brain barrier func tion in vivo has been published elsewhere (Wahl et aI., 1984) . Essential features of the experimental procedure are briefly summarized here. A craniectomy of 1.5 x 2.0 cm was performed in the right parietal region of the skull.
A fluid reservoir was made around the opening with a rapidly polymerizing dental cement. Two plastic tubes perforating the wall of the reservoir served for superfu sion of the exposed cerebral cortex. The brain and dura were then covered with a layer of 3-4 cm of paraffin oil. The pia arachnoidea preparation was used for experi mentation only when no extravasation of barrier indica tors was found during the control phase. The cerebral cortex was superfused then with bradykinin in increasing concentrations. The bradykinin superfusate was prepared from a freshly made stock solution of 4 x 10-3 M bra dykinin triacetate (Serva, Heidelberg, F.R.G.) dissolved in artificial CSF. The concentration of the bradykinin so lution was tested by a rat uterus bioassay according to Diniz et al. (1961) as modified by Mann et al. (1976) . des
Arg-9-Bradykinin and des-Arg-9-Leu-8-bradykinin were 
Statistical analyses
Vessel diameter values are means :t SEM expressed as a percentage of the control values that were obtained during superfusion with artificial CSF. Changes in vessel diameter were statistically evaluated after testing for normal distribution by t test using the sequentially rejec tive Bonferroni procedure to ensure the multiple level of significance (Holm, 1979) . A 95% confidence level was considered significant.
RESULTS

Effect of cortical superfusion with bradykinin on arterial vessels
The resting diameter of the arteries investigated had a range of 60-250 ]-Lm. Mean arterial diameter (± SEM) was 146.1 ± 12.0 ]-Lm. Cortical superfu sion with artificial CSF did not significantly affect the diameters of the pial arteries. The diameters were minimally reduced to 97.2 ± 2.1% after 1 min and to 99.5 ± 1.6% after 30 min of superfusion. Superfusion with bradykinin in doses of 4 x 10-9 and 4 x 10-8 M had no effect. Superfusion with doses of 4 x 10-7 to 4 X 10-4 M resulted in a dose dependent dilatation ( Fig. I) . One minute after the start of superfusion with 4 x 10 -6 M bradykinin, arterial dilatation was statistically significant (p < 0.05). A dilating response to 140 ± 4.5% was the maximum that was obtained at concentrations of 4 x 10-5 M. At concentrations of 4 x 10-4 M, ar terial dilatation became somewhat attenuated to 130.4 ± 4.7%. This, however, was statistically non significant from the maximal dilating response. As a rule, arterial vessels were found to develop the maximum of dilatation within 30 s after the start of superfusion. The dilating response, however, be came attenuated with continued exposure (Fig. I) .
After 30 min of superfusion, arterial dilatation al- 
Dose-response curves of pial artery dilatation to bra dykinin (4 x 10-7 to 4 X 10-4 M) obtained 1 and 30 min after the start of superfusion, Arteries of a resting diameter of 60-250 fLm were investigated, The con centrations of bradykinin in the superfusate are given along the abscissa, the changes (mean ± SEM) in the diameters as per centages of control along the ordinate, n, number of vessels studied, *p < 0,05, or smaller. most always was easing off, especially at higher concentrations. Doses of 10 -5 M elicited a signifi cant dilatation to 122.2 ± 4.8%, whereas doses of 4 x 10-4 M induced dilatation to only 107.6 ± 4. 1% of normal. A relationship between the vessel diameter in thp resting state and the reaction to bradykinin could not be established.
Effect of cortical superfusion with bradykinin on venous vessels
The veins studied had a resting diameter of 50-270 fJ-m (mean ± SEM, 1I5.7 ± 11.4 fJ-m). No sig nificant reaction to the cortical administration of artificial CSF was found, either 1 min (104.6 ± 10 T Q;
Bradykinin 1.2%) or 30 min (104.7 ± 1.1%) after the start of superfusion.
The diameter of pial veins remained virtually un changed at all concentrations tested ( Fig. 2 ) 1 min after administration of bradykinin. If at all, a slight reduction of the vessel diameters seemed to occur preferentially, although opposite reactions were oc casionally observed.
However, with continuing duration of exposure, the reduction of venous diameter by bradykinin was found clearly to prevail. Thirty minutes after the administration of 4 x 10-9 to 4 x 10 -7 M brady kinin, no effect was observed. As shown in Fig. 2 (right), 4 x 10 -6 M bradykinin yielded a statisti cally significant reduction of the venous vessel di- bradykinin (4 x 10-9 to 4 X 10-3 M) obtained 1 and 30 min after the start of exposure. Bra dykinin concentrations in the superfusion fluid are given along the abscissa, the venous diameters (mean ± SEM) as percentages of control along the ordinate. n, number of ves sels studied. *p < 0.05, or smaller.
Duration of application: 1 min
Duration of application: 30 min -30 n = 1 a n ",21 n -19 n = 16 n '" 11 4xl0-7 4xl0-5 4xl0-3
Bra'dykinin r MJ ameter. At this concentration, a mean value of 91.9 ±3. 1 % of normal was found. A maximal reduction to 84 ± 2.5% was obtained 30 min after superfusion with 4 x 10-3 M. No correlation was found be tween the venous reaction to bradykinin and the resting venous diameter.
Effect of superfusion with bradykinin on _ blood-brain barrier permeability
In control experiments, superfusion of the cere bral surface with artificial CSF was extended up to 4 h. Penetration of blood-brain barrier markers, ei ther Na + -fluorescein or FITC-dextran, from the in travascular space into the brain parenchyma was not found, however (Wahl et aI., 1984) .
A bradykinin concentration of 10-9 M never in duced extravasation of any tracer tested.
' The ef fects of bradykinin in concentrations from 4 x 10-8 to 4 X 10-3 M on the permeability of pial vessels are given in Ta ble 1. FITC-albumin (mol wt 67,000), and FITC-dextran (mol wt 62,000 or 19,400) were never observed to leave the intravascular space, even after the administration of maximal concen trations of bradykinin, i.e., 4 x 10-3 M. When Na + -fluorescein was employed as the low molec ular weight blood-brain barrier indicator instead, bradykinin concentrations of 4 x 10 -6 M sufficed to induce leakage of the marker into the paren chyma (Fig. 3) . The minimal concentration of bra dykinin found in a single experiment to induce ex travasation of Na + -fluorescein was as low as 4 x 10 -7 M. Extravasation of the indicator began as single fluorescent spots around small venules and became diffuse and generalized with duration of the exposure and with higher concentrations. Figure 3b gives an example of an advanced state of extrava sation. The [3-receptor agonist isoproterenol in a concen tration of 5 x 10 -6 M has been shown to antagonize an increase in the permeability of peripheral vessels caused by 10-7 M bradykinin (Svensjo et aI., 1979) .
In the present study, 4 x 10-6 M bradykinin was found to induce leakage of cerebral vessels. There fore, an equivalent inhibitory concentration of 10-4 M isoproterenol was used in view of the above-men tioned studies of Svensjo et al. Na + -fluorescein was given as the blood-brain barrier indicator. Ta ble 2 summarizes our findings. Isoproterenol adminis tered from the extravascular side of the blood brain barrier led to a reduction of the fluorescein leakage induced by bradykinin. The minimally ac tive concentration of bradykinin that caused extra vasation of the marker under control conditions, i.e., without isoproterenol, was 4 x 10-7 M, whereas in the presence of the [3-adrenergic com pound, a concentration of 4 x 10-5 M was required to induce leakage. Bradykinin concentrations of 4 x 10-6 M were observed in all experiments to en hance the passage of fluorescein when isoproter enol was omitted, whereas bradykinin concentra tions one to two orders of magnitude higher were necessary when isoproterenol was added.
Antagonism of the permeability-enhancing effect of bradykinin by isoproterenol is illustrated in Fig.  4 . Addition of isoproterenol to the superfusate had no effect on the resting diameter of the pial vessels. Interestingly, the [3-stimulatory agent did not alter the vasomotor reactivity of either arteries or veins to bradykinin. Arteries were found to dilate to the same extent upon administration of any bradykinin concentration as they did without isoproterenol. The maximal arterial dilatation, i.e., to 135.8 ± 3.7% of normal, was obtained at bradykinin con centrations of 4 x 10-5 M. The reduction of the venous diameter by bradykinin was also virtually unaffected by the addition of isoproterenol.
Effect of intraarterial infusion of bradykinin on pial vessels
Bradykinin was intraarterially infused in another group of experiments to study if it affected perme-TABLE 1. Effe ct of topical administration of bradykinin (4 X 10-8 to 4 X 10-3 M) on permeability of pial vessels jiJr diff erent indicators Blood-brain barrier indicator Na + -fluorescein (mol wt 376) (n = 6) FITC-dextran (mol wt 19,400) (n = 3) FITC-dextran (mol wt 62,000) (n = 4) FITC-albumin (mol wt 67,000) (n = 1)
Extravasation at bradykinin concentration (M) of: 4 X 10-8 4 X 10-7 4 X 10-6 4 x 10-5 4 X 10-4 4 X 10-3 n = I n = 5
The blood-brain barrier indicators were strictly confined to the intravascular space under normal conditions. Duration of exposure to a given concentration was 30 min. (-), no extrava sation; FITC, fluorescein-isothiocyanate -labeled. Eff ect of cortical superfusion of bradykinin (4 x 10-7 to 4 X 10-4 M) simultaneollsly with I-isoproterenol (10-4 M)
Oil permeability of pial vessels for Na + -fluorescein Extravasation at bradykinin concentration ( M ) of: Blood-brain barrier indicator 4 X 10-7 4 X 10-6 4 X 10-5 4 X 10-4
Bradykinin (n = 6) Bradykinin + isoproterenol (n = 5) Na --fluorescein (mol wt 376) Na � -fluorescein (mol wI 376) (-) . no extravasation.
ability and vasomotor behavior from the intravas cular side. For control, artificial CSF was infused for 30 min at a rate of 1.0 ml/min. The control so lution had no effect on the resting diameters of pial arteries or veins and did not produce leakage of Na + -fluorescein. Bradykinin was infused in con centrations of 10-3 M at a rate of 1 mIlmin. Initially, there was a brief fall of arterial blood pressure for �30-40 mm Hg during 1-2 min (from �13S to 90-100 mm Hg; in one experiment, to 70 mm Hg at the lowest). The pial arteries dilated to I I S-120% during this episode. In the following period, arterial blood pressure recovered to an almost normal level (i.e., to �120-12S mm Hg). A minimal arterial di latation of approximately + S% during this steady state of intraarterial infusion of bradykinin is inter preted as a normal autoregulatory response (Wahl and Kuschinsky, 1979b) . Figure S demonstrates the effect of the intravas cular administration of bradykinin (10-3 M, 1 mIl min) on the permeability of pial vessels to Na 1fluorescein. As shown, this route of administration also induced massive leakage of the low molecular weight barrier indicator, as was found upon cortical superfusion with bradykinin. If, however, infusion rates of bradykinin were only 0. 1 -O.S mIlmin, ex travasation of Na + -fluorescein into the parenchyma did not occur. On the other hand, leakage of the high molecular weight indicator FlTC-dextran (mol wt 62,000) was never found, either at high or at low infusion rates. In a different set of experiments (un published data) using the same infusion rates, con centrations of bradykinin were determined in the sagittal sinus as an estimate of the peptide level active in the intravascular bed during arterial infu sion. Kinin concentrations of 4-6 x 10-6 M were found, which are surprisingly close to the level found effective to open the blood-brain barrier when bradykinin was employed for cerebral super fusion.
DISCUSSION
Under physiological conditions, concentrations of kinins are low or even absent in cerebral tissue as well as in the intravascular space (Shikimi et aI., 1973; Erdos, 1979; Regoli and Barabe, 1980; Maier Hauff et aI., 1984) . However, in cerebral injury leading to opening of the blood-brain barrier, plasma kininogens enter the cerebral parenchyma through the barrier defect (Baethmann et aI., 198 1; Maier-Hauff et aI., 1984) . Formidable amounts of kinins may be released under these circumstances in the affected brain tissue. Maier-Hauff et al. (1984) observed the release of kinins in areas of cold injury vasogenic edema on the order of SOo-700 ngl g fresh tissue within 3-7 h after the insult. In ad dition, the release of kinins in the intravascular compartment has been reported in local ischemia of the forearm (Bavazzano et aI., 1970) . Therefore, it seemed worthwhile to investigate the effect of bra dykinin on the cerebral vasculature administered from both sides of the vascular wall as an experi mental model of an activation of the kallikrein kinin system in the brain.
An important question of our model is whether the pial vasculature is representative for cerebral vessels with respect to vasomotor reactivity and permeability. A similar vasomotor behavior of the extra-and intraparenchymal cerebral vessels has often been shown lfor review see Kuschinsky and Wahl (1978) ]. Evidence for the impermeability of pial vessels to intravascular material used as barrier indicators, such as Evans blue, peroxidase, Na + fluorescein, FITC-dextran, and FITC-albumin, has been provided by several groups (Rapoport et al., 1972; Westergaard and Brightman, 1973; Hultstrom et aI., 1983; Wahl et aI., 1984) .
The present study revealed that bradykinin in duces a concentration-dependent dilatation of pial arteries in situ. The finding is in agreement with Thirty minutes after exposure to artificial CSF (control); b: 30 min after superfusion with 4 x 10-6 M bradykinin plus 1 x 10-4 M isoproterenol; c: 30 min after superfusion with 4 x 10-5 M bradykinin plus 1 x 10-4 M isoproterenol. In the presence of isoproterenol, leakage of fluorescein was not seen (b) at a bradykinin concentration of 4 x 10-6 M, which was effective to open the barrier when isoproterenol was omitted. At higher concentrations of bradykinin (c), isoproterenol did not afford protection against opening of the barrier. Calibration lines, 400 f.lm. 4 (cant'd.) . See legend opposite.
other in vivo observations on feline pial arteries and with in vitro studies on cerebral arteries of different species (Wahl et aI., 1983a,b; Whalley and Wahl, 1983) . When comparing the dilating potency of bra dykinin as assessed during microapplication to pial arteries (Wahl et a!., 1983a) with that assessed during superfusion of the pia arachnoidea, a differ ence in the dose-response relationship becomes obvious. Concentrations of bradykinin approxi mately four times higher were necessary to induce dilatation by superfusion of the vessels to the same level as that induced by microapplication. Still, the dose-effect curve as well as the maximal dilating response were similar under both experimental con ditions. Maximal dilatation was + 40% by superfu sion and + 44% by microapplication. Bradykinin concentrations required to attain maximal dilatation were 4 x 10-5 M during superfusion and 1 x 10-5 M during microapplication. Cortical superfusion may induce not only mere direct vascular effects, but also indirect effects owing to alterations of the cerebral metabolism. The cerebral administration of 10-6-10-5 M bradykinin by ventriculocisternal per fusion in cats did not reveal an increase of CMR02, but rather an enhancement of the cerebral uptake of glucose. However, the electrical activity (EEG) was depressed rather than stimulated (Unterberg et aI., 1983) . These findings do not explain the lowered sensitivity of pial arteries to bradykinin during cor tical superfusion.
The dilating response to bradykinin was not af fected by the simultaneous administration of iso proterenol. This finding points out that superfusion with 10-4 M isoproterenol probably has no cerebral metabolic effects either, since a possible increase of the cerebral metabolism owing to the fj-stimulatory agent should be associated with an increased arte rial dilatation. Furthermore, this observation is in line with previous reports, where isoproterenol even in high concentrations had negligible effects on pial arteries (Wahl et aI., 1974) . Dilatation of pial arteries became attenuated during 30 min of contin uous superfusion, which, however, cannot be at tributed to the degradation of kinins in the super fusion fluid or loss by diffusion into adjacent CSF spaces. In measurements of kinins in the super fusate sampled at different periods after exposure, the concentrations were almost unchanged. There fore, attenuation of the dilating response to brady kinin appears most likely to have resulted from de sensitization of the preparation rather than from a fall of the effective concentration of kinins at the vascular surface.
Another point is whether the vasomotor effects of pial vessels elicited by bradykinin were induced directly by a specific interaction through receptors Thirty minutes after intracarotid infusion of artificial CSF at a rate of 1 ml/min (control); b: 30 min after intraarterial administration to bradykinin (10-3 M, 1 ml/min) dissolved in artificial CSF, leading to cerebrovenous concentrations of 4-6 x 10-6 M. As seen, this route of administration led also to diffuse extravasation of the marker into the parenchyma. In contrast to the administration of bradykinin by cortical superfusion, arterial dilatation did not occur. Calibration lines, 400 fLm. on the vascular smooth muscle cells or indirectly by secondary mediators. Cherry et al. (1982) and Furchgott et al. (1983) have proposed the vaso motor effects of bradykinin to be mediated by the release of endothelial factors. However, since intra vascular administration of bradykinin did not in duce specific changes of the vascular diameter contrary to extravascular administration-media tion by endothelial factors of the vasodilation caused by superfusion of the brain with bradykinin seems rather unlikely. Prostaglandins appear not to be involved in the bradykinin-induced dilatation, because relaxation could be elicited in isolated ce rebral arteries in the presence of indomethacin (Whalley and Wahl, 1983) to the same extent as without indomethacin (Wahl et aI., 1983a) . We sup pose that bradykinin dilated cerebral arteries by in teraction with B2-receptors on the smooth muscle. This conclusion is based on findings obtained with a selective BI-receptor agonist and antagonist, i.e., des-Arg-9-bradykinin and des-Arg-9-Leu-8-brady kinin, respectively. The BI-agonist did not induce a vasomotor reaction, and the B I -antagonist did not inhibit dilatation caused by bradykinin, which is in accordance with previous findings (W halley and Wahl, 1983) . Furthermore, since intravascular ap plication of bradykinin failed to reveal specific ar terial dilatation, we assume that the peptide did not reach these Brreceptors on smooth muscle cells in effective concentrations.
Several mechanisms may be considered to have led to a reduction of the venous diameter, such as active contraction (Auer and Loew, 1983; Ed vinsson et aI., 1983) , release of secondary media tors, swelling of the venous endothelial cells, and adherence of leukocytes to the endothelial surface.
Administration of bradykinin from both sides of the vessel wall led to the extravasation of Na + -flu orescein into the extravascular space, however, not of larger indicators, such as FITC-dextran (mol wt 19,400 and 62,000) and FITC-albumin (mol wt 67,000). This observation suggests that bradykinin induces selective rather than gross opening of the blood-brain barrier. Considering the hydrodynamic molecular radius of the different barrier indicators used (Table 3) , we conclude that bradykinin opened functional pores in the endothelial layer of at least 11-15 A in diameter. Opening of even larger pores, up to 60 A but no more, might be considered. A diameter of 60-65 A corresponds to the hydrody namic Stokes' radius of FITC-dextran (mol wt 19,400), which remained confined to the intravas cular lumen during exposure to bradykinin.
The opening of pial vessels by bradykinin is prob ably mediated through endothelial B2-receptors. This conclusion is based on the experimental find ings mentioned above that neither a BI-agonist nor -antagonist affected permeability, the latter in the presence of bradykinin.
Comparing the cerebrovascular effects of brady kinin with those of histamine, both substances cause dilatation of pial arteries upon topical admin istration (Wahl and Kuschinsky, 1979a) . Contrary to the action of bradykinin, opening of the blood brain barrier by topically administered histamine does not occur (Bromann and Lindberg-Bromann, 1945 ), which has been tested with trypan blue. The intraarterial infusion of histamine was found to in duce edema together with an enhanced passage from blood to brain of sucrose, aminoisobutyric acid, and horseradish peroxidase, indicative of gross opening of the blood-brain barrier (Dux and Joo, 1982; Gross et aI., 1982) . Unselective opening of the barrier by the intravascular administration of histamine is in contrast to the selective opening of the barrier by bradykinin acting from the intra-or extravascular side. Therefore, it may be assumed that the two substances are involved differently in conditions of blood-brain barrier dysfunction.
Reduction of bradykinin-induced leakage by iso proterenol in a certain concentration range has also been found in the peripheral circulation (Svensjo et aI., 1979) . and believe that isoproterenol inhibits the bradykinin-induced leakage by the relaxation of en dothelial cells, which were considered to be con tracted by bradykinin. In cerebral vessels, an opening of interendothelial pathways is an opening of tight junctions, which is considered a cause of breakdown in the hyperosmolarity-induced disrup tion of the blood -brain barrier (Rapoport et aI., 1972 (Rapoport et aI., , 1978 . Alternatively, enhancement of trans endothelial vesicular transport, as reported after the cerebral administration of serotonin (Westergaard, 1977) , might also be considered a mechanism of ex travasation. However, the induction of pinocytosis by bradykinin seems unlikely, since transport of larger molecules into the brain should also be in creased, which was not found in the present study.
A mere distension of the endothelial layer by di latation associated with an enlargement of the vas cular surface as the only mechanism of bradykinin induced extravasation can be rejected, since vaso dilation of pial vessels to a similar extent could be induced by xanthine oxidase, where the vascular permeability, even to Na + -fluorescein, remained normal (Wahl et aI., 1984) .
We therefore conclude that bradykinin specifi cally increases the permeability of the blood-brain barrier for small molecules. The assumption that bradykinin-induced leakage is an entirely mechan ical phenomenon can furthermore be rejected, in view of the fact that during the intravascular appli cation of bradykinin, leakage of fluorescein is not associated with arterial dilatation or reduction of venous vessel diameter.
In conclusion, our findings demonstrate that small amounts of kinins administered to the brain suffice to induce marked changes of the cerebral microcirculation, such as arterial dilatation and re duction of venous diameter, together with a selec tive opening of the blood -brain barrier to small molecules. The concentrations of bradykinin found effective to enhance the permeability of the pial ves sels or to induce microcirculatory changes were in a range that has been found in cerebral tissue during vasogenic brain edema secondary to a focal lesion (Baethmann et aI., 1981; Maier-Hauff et aI., 1984) . The enhancement of blood-brain barrier perme ability together with the microcirculatory changes induced by bradykinin are important enough to render the kallikrein-kinin system a serious can didate for mediator in pathological processes, such as brain edema.
